Trifluoroacetic acid → 4-[(4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-6-methyl-5-oxo-7-(propan-2-yloxy)-2,3,4,5-tetrahydro-1,4-benzoxazepine-9-carbonitrile

Temperatur

120 °C

To a solution of 4-((2-(benzyloxy)-4,6-dimethylpyridin-3-yl)methyl)-9-bromo-7-isopropoxy-6-methyl-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one (116 g, 98 mg, 0.18 mmol) in N,N-dimethylacetamide (2 mL) was added cuprous cyanide (50 mg, 0.55 mmol). The reaction mixture was heated at 120° C. in a sealed tube for 20 hours, cooled to room temperature then additional cuprous cyanide (25 mg, 0.26 mmol) was added and the reaction was heated at 150° C. in a sealed tube for 5 hours. The reaction was cooled to room temperature, diluted with water (5 mL) and extracted with methyl tert-butyl ether (2×5 mL). The combined organic layers were washed with brine (5 mL), dried over magnesium sulfate and concentrated under vacuum. The crude residue was taken up in dichloromethane (0.5 mL) and trifluoroacetic acid (0.5 mL, 2 mmol) and stirred at room temperature overnight then concentrated under vacuum. The residue was purified by reverse phase HPLC to provide the title compound (Example 116, 13 mg, 19% yield). 1H NMR (700 MHz, DMSO-d6) δ 7.47 (s, 1H), 5.93 (br. s., 1H), 4.58-4.69 (m, 3H), 4.12 (br. s., 2H), 2.19 (d, J=12.91 Hz, 6H), 2.14 (s, 3H), 1.26 (d, J=6.02 Hz, 6H): MS 396 [M+H].

1. temperaturecooled to room temperature
2. temperaturethe reaction was heated at 150° C. in a sealed tube for 5 hours
3. temperatureThe reaction was cooled to room temperature
4. extractionextracted with methyl tert-butyl ether (2×5 mL)
5. washThe combined organic layers were washed with brine (5 mL)
6. dry with materialdried over magnesium sulfate
7. concentrationconcentrated under vacuum
8. concentrationthen concentrated under vacuum
9. customThe residue was purified by reverse phase HPLC

ORD-Eintrag

ord-a5ede1a6b6974befa8fa8fd70a73f209

Quelldatensatz

uspto-grants-2015_05

DOI

10.6084/m9.figshare.5104873.v1

Patentnummer

US09040515B2